PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Hypoglycemia Clinical Trial

Official title:

Comparison of Pharmacokinetic and Pharmacodynamic Profiles of G-Pump™ (Glucagon Infusion) vs. GlucaGen® Delivered Subcutaneously to Subjects With Type 1 Diabetes (T1DM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02081001
• Other study ID #: XSGO-201
• Secondary ID: 4R44DK096706-02
• Status: Completed
• Phase: Phase 2
• First received: March 4, 2014
• Last updated: March 10, 2018
• Start date: March 2014
• Est. completion date: September 2014

Study information

• Verified date: March 2018
• Source: Xeris Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: September 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males or females diagnosed with type 1 diabetes mellitus for at least 24 months

• Current usage of subcutaneous insulin pump treatment

• Age 18-65 years

• C-peptide level < 0.5 ng/ml

• Willingness to follow all study procedures, including attending all clinic visits

• Subject has provided informed consent and has signed and dated an informed consent form before any trial-related activities

Exclusion Criteria:

• Pregnant and/ or Lactating: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.

• HbA1c >10.0%

• Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)

• Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum bilirubin of over 2.0.

• Hematocrit of less than or equal to 34%

• Congestive heart failure, NYHA class II, III or IV

• History of coronary artery disease

• Active foot ulceration

• History of a cerebrovascular accident

• Active alcohol abuse or substance abuse

• Active malignancy, except basal cell or squamous cell skin cancers

• Major surgical operation within 30 days prior to screening

• Seizure disorder

• Current administration of oral or parenteral corticosteroids

• Use of an investigational drug within 30 days prior to screening

• Bleeding disorder, treatment with warfarin, or platelet count below 50,000

• Proliferative or severe non-proliferative retinopathy

• Gastroparesis

• Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)

• Insulinoma

• Allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products.

• Glycogen storage disease

• Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen

• Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.

• Any reason the principal investigator deems exclusionary

Related Conditions & MeSH terms

• Hypoglycemia

Intervention

Drug:
• Novo Nordisk GlucaGen®
single subcutaneous infusion doses at 0.3 µg/kg, 1.2 µg/kg and 2.0 µg/kg
• G-Pump™ (glucagon infusion)
single subcutaneous infusion doses at 0.3 µg/kg, 1.2 µg/kg and 2.0 µg/kg

Locations

Country	Name	City	State
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
Xeris Pharmaceuticals	Emissary International LLC, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early)	The onset of action was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucose following each dose of glucagon.	0 to 150 minutes post-dosing
Primary	Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early)	The speed of absorption was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucagon following each dose of glucagon.	0 to 150 minutes post-dosing
Secondary	Glucagon Cmax	Maximum plasma concentration of glucagon	From 0 to 150 minutes post-dosing
Secondary	Glucose Cmax	Maximum plasma concentration of glucose	From 0 to 150 minutes post-dosing
Secondary	Glucagon Tmax	Time to maximum plasma concentration of glucagon	From 0 to 150 minutes post-dosing
Secondary	Glucose Tmax	Time to maximum plasma concentration of glucose	From 0 to 150 minutes post-dosing
Secondary	Glucagon AUC	Area under the plasma concentration time curve for glucagon	From 0 to 150 minutes post-dosing
Secondary	Glucose AUC	Area under the plasma concentration time curve for glucose	From 0 to 150 minutes post-dosing
Secondary	Infusion Site Discomfort Score at 10 Minutes	Infusion site discomfort was assessed by the subjects using a 100 mm Visual Analog Scale (VAS) questionnaire at 10 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.	At 10 minutes post-dosing
Secondary	Infusion Site Discomfort Score at 30 Minutes	Infusion site discomfort was assessed by the subject using a 100 mm Visual Analog Scale (VAS) questionnaire at 30 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.	At 30 minutes post-dosing